骨髓增生异常综合征骨髓原始细胞祖细胞体外培养

TREATMENT OF MYELCOYSPLASTIC SYNDROMES ANDITS SECONDARY ACUTE MYELOID LEUKEMIAS WITHORDINARY DOSE COMBINATION CHEMOTHERAPY

以植物血凝素－白细胞条件培养液（ＰＨＡ－ＬＣＭ）作为刺激源，研究确定了白血病原始细胞祖细胞（ＢＣＰ）体外培养方法的一些细节。用此方法观察了骨髓增生异常综合征（ＭＤＳ）患者去除Ｔ细胞和粘附细胞的骨髓单个核细胞中ＢＣＰ体外生长情况。２７例ＭＤＳ中１０例（３７％）有原始细胞集落（ＢＣＣ）生长。ＢＣＣ阳性率和产率与ＦＡＢ亚型之间有一定的相关性；阳性率并与姐妹染色单体分化（ＳＣＤ）显著相关。对照组中无一例有ＢＣＣ生长。本文结果表明ＢＣＰ能够反映ＭＤＳ的恶性细胞克隆；ＢＣＣ是评估ＭＤＳ病期的重要生物学指标。

he treatment of myeledysplastic syndromes(MDS)and its secondary acute myeloid leukemias(SAML)isstill a difficult problem in clinical practice, and there isstill much controversy over the role for ordinary dose ofcombination chemotherapy (ODCC) in the disease. Wereported our results of treatment of 7 MDS and 11SAML patients with ODCC. The complete remissionrate was 35% and partial remission rate 12%. Only twotherapy-related death occurred in the whole group. Weconcluded that it was feasible to treat selected cases ofMDS with ODCC.